Thermo Fisher Scientific (TMO) to Release Earnings on Thursday

Thermo Fisher Scientific (NYSE:TMO) is projected to issue its Q4 2025 results before the market opens on Thursday, January 29th. Analysts expect the company to announce earnings of $6.44 per share and revenue of $11.9519 billion for the quarter. Individuals can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, January 29, 2026 at 8:30 AM ET.

Thermo Fisher Scientific Trading Up 0.1%

NYSE:TMO opened at $626.82 on Tuesday. Thermo Fisher Scientific has a 52-week low of $385.46 and a 52-week high of $643.99. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. The stock has a fifty day simple moving average of $592.07 and a 200-day simple moving average of $533.76. The company has a market capitalization of $235.50 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 4.11 and a beta of 0.91.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Shareholders of record on Monday, December 15th were issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend was Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Thermo Fisher Scientific announced that its board has approved a stock repurchase plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at Thermo Fisher Scientific

In related news, COO Michel Lagarde sold 32,000 shares of the firm’s stock in a transaction that occurred on Wednesday, December 3rd. The shares were sold at an average price of $583.39, for a total value of $18,668,480.00. Following the sale, the chief operating officer directly owned 65,480 shares of the company’s stock, valued at approximately $38,200,377.20. This trade represents a 32.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Frederick M. Lowery sold 6,913 shares of Thermo Fisher Scientific stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $597.68, for a total value of $4,131,761.84. Following the completion of the transaction, the executive vice president directly owned 14,367 shares in the company, valued at $8,586,868.56. This represents a 32.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 124,517 shares of company stock worth $72,363,568. 0.33% of the stock is owned by insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of hedge funds have recently made changes to their positions in the business. Revolve Wealth Partners LLC increased its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares in the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. boosted its position in shares of Thermo Fisher Scientific by 0.7% in the third quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 2,960 shares of the medical research company’s stock worth $1,436,000 after buying an additional 20 shares during the period. Challenger Wealth Management grew its stake in shares of Thermo Fisher Scientific by 3.1% in the second quarter. Challenger Wealth Management now owns 735 shares of the medical research company’s stock valued at $298,000 after buying an additional 22 shares in the last quarter. Security National Bank of Sioux City Iowa IA raised its holdings in shares of Thermo Fisher Scientific by 0.3% during the 2nd quarter. Security National Bank of Sioux City Iowa IA now owns 6,549 shares of the medical research company’s stock valued at $2,655,000 after buying an additional 22 shares during the period. Finally, Deerfield Management Company L.P. boosted its holdings in Thermo Fisher Scientific by 3.1% in the 3rd quarter. Deerfield Management Company L.P. now owns 944 shares of the medical research company’s stock worth $458,000 after acquiring an additional 28 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TMO. Redburn Partners set a $580.00 price objective on shares of Thermo Fisher Scientific in a research note on Wednesday, October 8th. Leerink Partners raised their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 22nd. Weiss Ratings restated a “hold (c)” rating on shares of Thermo Fisher Scientific in a research report on Friday, January 9th. The Goldman Sachs Group assumed coverage on Thermo Fisher Scientific in a research report on Tuesday, December 9th. They set a “buy” rating and a $685.00 price objective for the company. Finally, Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $625.47.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.